Teleflex Incorporated (NYSE:TFX) Holdings Lifted by New York Life Investment Management LLC

New York Life Investment Management LLC grew its holdings in shares of Teleflex Incorporated (NYSE:TFX) by 63.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,139 shares of the medical technology company’s stock after purchasing an additional 4,717 shares during the period. New York Life Investment Management LLC’s holdings in Teleflex were worth $3,027,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC boosted its position in shares of Teleflex by 33.3% in the 4th quarter. Venturi Wealth Management LLC now owns 184 shares of the medical technology company’s stock valued at $46,000 after purchasing an additional 46 shares during the period. Huntington National Bank boosted its holdings in shares of Teleflex by 26.5% in the third quarter. Huntington National Bank now owns 253 shares of the medical technology company’s stock worth $50,000 after buying an additional 53 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd increased its position in shares of Teleflex by 1.5% in the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 3,767 shares of the medical technology company’s stock worth $740,000 after acquiring an additional 56 shares in the last quarter. Lindbrook Capital LLC raised its holdings in shares of Teleflex by 75.3% during the fourth quarter. Lindbrook Capital LLC now owns 135 shares of the medical technology company’s stock valued at $34,000 after acquiring an additional 58 shares during the period. Finally, Wahed Invest LLC lifted its position in shares of Teleflex by 10.4% in the 3rd quarter. Wahed Invest LLC now owns 733 shares of the medical technology company’s stock valued at $144,000 after acquiring an additional 69 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Trading Up 2.2 %

Shares of NYSE TFX opened at $203.01 on Monday. The business has a 50 day simple moving average of $217.27 and a 200 day simple moving average of $226.57. Teleflex Incorporated has a 52 week low of $177.63 and a 52 week high of $262.97. The stock has a market cap of $9.56 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 1.95 and a beta of 1.13. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 2.51.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, May 2nd. The medical technology company reported $3.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.14. Teleflex had a net margin of 9.82% and a return on equity of 14.78%. The firm had revenue of $737.80 million during the quarter, compared to analysts’ expectations of $726.85 million. During the same period in the previous year, the company earned $3.09 earnings per share. The company’s revenue was up 3.8% compared to the same quarter last year. On average, research analysts predict that Teleflex Incorporated will post 13.72 earnings per share for the current fiscal year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.67%. The ex-dividend date was Thursday, February 29th. Teleflex’s payout ratio is 21.83%.

Insider Buying and Selling at Teleflex

In other news, VP Cameron P. Hicks sold 7,401 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the completion of the sale, the vice president now owns 10,050 shares in the company, valued at approximately $2,261,250. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.43% of the company’s stock.

Analyst Upgrades and Downgrades

TFX has been the topic of several recent analyst reports. Royal Bank of Canada cut their target price on shares of Teleflex from $272.00 to $265.00 and set an “outperform” rating on the stock in a research note on Friday, February 23rd. StockNews.com downgraded Teleflex from a “buy” rating to a “hold” rating in a research note on Friday, February 23rd. Needham & Company LLC restated a “hold” rating on shares of Teleflex in a research report on Friday. Truist Financial dropped their target price on Teleflex from $240.00 to $219.00 and set a “hold” rating on the stock in a report on Friday. Finally, JMP Securities restated a “market outperform” rating and set a $285.00 price target on shares of Teleflex in a report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $261.75.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.